Loading...

DGX - Quest Diagnostics Incorporated

Analyst Upgrade Signal for 02-07-2024
Analyst Upgrade Signal: DGX from Hold to Buy by Jefferies
Price Target: $140>>155



Stock Signal Information


Signal

Analyst Upgrade Stock
Report Date: 02-07-2024
Symbol: DGX - Quest Diagnostics Incorporated
Sector: Healthcare
Industry: Diagnostics & Research
Analyst Upgrade Signal: DGX from Hold to Buy by Jefferies
Price Target: $140>>155

  DGX Technical Chart

Company Contact

Quest Diagnostics Incorporated (DGX)
500 Plaza Dr
Secaucus, NEW JERSEY 07094
Phone: 19735202700
Website: http://www.questdiagnostics.com
CEO: Mr. Stephen Rusckowski


Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationships with Clinical Genomics Pty Ltd and Anthem Inc. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.